Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Small Caps buck the trend
Thu, 8 Nov 11:30 am

Indian equity markets continue to trade weak over the last two hours of trade. Auto and consumer durables stocks witnessed maximum buying interest while capital goods and IT stocks witnessed maximum selling pressure.

The Sensex today is down by 52 points, while the NSE-Nifty today is down by 22 points. BSE Mid Cap index is down by 0.09% while the BSE Small Cap index is up by 0.09%. The rupee is trading at 54.45 to the US dollar.

Hotel stocks are trading in the red led by Oriental Hotels and Hotel Leela Venture. Indian Hotel Company Limited (IHCL) has announced results for the quarter ended September 2012. Net sales for 2QFY13 increased by 6% YoY. This is despite the first two quarters usually being the leanest period for the industry. Operating margins saw a decline of 5.5% YoY. This has been due to increase in overall costs which saw a rise of 12.5% YoY. Operating profits declined by 47.6% YoY. The company posted a net loss as compared to a net profit for the same period last year. This was due to surging operating costs and high tax provisions and the global economic uncertainty which curbed spending on travel. On a consolidated basis, for the half year ended September 2012, the company reported a 14.5% YoY increase in net sales and a wider net loss of Rs 909 m as compared to a net loss of Rs 703 m in the same period last year.

Pharma stocks are trading in the green led by Biocon Limited and Indoco Remedies. As per a leading daily, the cabinet will discuss the new pharma policy, National Pharmaceutical Pricing Policy today. The policy is aimed at capping the prices of 348 essential medicines. This will likely decrease the prices of various expensive drugs. However, prices of a few low-priced medicines may increase. The prices of these 348 essential medicines will be capped at the weighted average of all drugs in a particular segment with more than 1% market share. After the cabinet clears this new policy, the Department of Pharmaceuticals will have to notify this before the Supreme Court's next hearing on the matter on November 27, 2012.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Small Caps buck the trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.